沙砾生物宣布完成超6亿元C轮融资，顺禧基金领投

Group 1 - The company, Beijing Shali Bio-pharmaceutical Co., Ltd., has completed over 600 million C-round financing, led by Shunxi Fund with participation from multiple investors [2] - Established in 2019, the company focuses on tumor immune cell therapy, developing TIL drugs for pan-solid tumors and on-demand cell therapies [2] - The core R&D platforms include StemTexp® for TIL expansion, StaViral® for stable viral strains, ImmuT Finder® for immune target discovery, and KOReTIL® for efficient gene knockout [2] Group 2 - The company's self-developed GT101 injection is the first TIL drug approved for clinical registration in China and is currently in critical Phase II clinical trials [2] - The global first membrane-bound IL-15 complex TIL product, GT201 injection, has completed IND submissions in both China and the U.S. and has been approved for Phase I clinical trials [2] - The company has developed a range of innovative products, including a dual-gene knockout autologous TIL therapy, mRNA vaccines targeting tumor neoantigens, and a universal CAR-iNKT cell therapy derived from stem cells, forming a product matrix for pan-solid tumor TIL drugs and on-demand cell therapies [2]